Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. International Stem Cell's annualized net income for the quarter that ended in Mar. 2026 was $-0.88 Mil. International Stem Cell's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-4.78 Mil. Therefore, International Stem Cell's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for International Stem Cell's Return-on-Tangible-Equity or its related term are showing as below:
ISCO's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.21 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
International Stem Cell (OTCPK:ISCO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
International Stem Cell Return-on-Tangible-Equity Related Terms
International Stem Cell Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for International Stem Cell's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell Return-on-Tangible-Equity Chart
ISCO vs ZVSA, AXIM, HEPA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, International Stem Cell's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
International Stem Cell (ISCO) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on International Stem Cell and its competitors. According to the industry distribution chart, International Stem Cell ranks #999999 out of 1199 companies in the Biotechnology industry.
Is International Stem Cell's Return-on-Tangible-Equity too high?
International Stem Cell's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, International Stem Cell ranks #999999 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, International Stem Cell has a GF Score™ of 30/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Return-on-Tangible-Equity compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #999999 out of 1199 companies for Return-on-Tangible-Equity. This places International Stem Cell in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on International Stem Cell and its competitors. International Stem Cell's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 27.2% above its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. International Stem Cell's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.17 is trading 27.2% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Modestly Overvalued.
Key valuation signals for ISCO:
Return-on-Tangible-Equity: 0.00%
GF Value™: $0.13 vs. price of $0.17 (27.2% above fair value)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
30GF Score
Get the complete analysis for ISCO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
